Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + olaparib for recurrent or metastatic cervical cancer (GOTIC-025)
jRCT2031210096Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and olaparib in cervical cancer (mCC), sponsored by Merck & Co. Started Jun 2021; status: completed.
02
Drugs
pembrolizumabolaparib
03
Conditions
cervical cancer (mCC)
Beyond the preview
Go deeper on jRCT2031210096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210096.